on GENEURO SA (EPA:GNRO)
GeNeuro SA announces the liquidation of its French subsidiary
GeNeuro SA, a Geneva-based biopharmaceutical company, announced that its French subsidiary, GeNeuro Innovation SAS, is in receivership. This decision was issued by the Lyon Economic Activities Court on July 15, 2025. SELARL MJ-Synergie has been appointed as receiver.
This liquidation comes as GeNeuro undergoes a restructuring process. In May, the company obtained a debt restructuring order in Switzerland, valid until September 28, 2025, which remains in effect despite the situation of its subsidiary. GeNeuro SA continues its efforts to develop treatments for neurodegenerative and autoimmune diseases.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENEURO SA news